Allscripts price target lowered to $11 from $16 at RW Baird Baird lowered its price target on Allscripts following its announcement management has concluded its exploration of strategic alternatives that did not produce a sale or merger of the company. The firm removed the takeout premium and believes investors should view the company as a long term investment with a conservative valuation. Shares remain Outperform rated.
News For MDRX From The Last 14 Days
Check below for free stories on MDRX the last two weeks.